Segment Data (Tables)

9 Months Ended

Sep. 24, 2021

Segment Reporting [Abstract]

Schedule of Segment Reporting Information by Reportable Segment

Selected information by reportable segment was as follows:

	Three Months Ended				Nine Months Ended
	September 24, 2021		September 25, 2020		September 24, 2021		September 25, 2020
Net sales:
Specialty Brands	$	359.7	$	539.6	$	1,149.6	$	1,553.0
Specialty Generics	147.5		159.4		462.0		512.7
Segment net sales	507.2		699.0		1,611.6		2,065.7
Medicaid lawsuit (Note 12)	—		(0.7)		—		(535.1)
Net sales	$	507.2	$	698.3	$	1,611.6	$	1,530.6
Operating income (loss):
Specialty Brands	$	189.9	$	291.8	$	588.6	$	765.0
Specialty Generics	15.2		43.1		73.8		155.5
Segment operating income	205.1		334.9		662.4		920.5
Unallocated amounts:
Corporate and unallocated expenses (1)	(20.8)		(42.1)		(69.1)		(152.3)
Depreciation and amortization	(168.4)		(236.1)		(506.1)		(675.5)
Share-based compensation	(2.4)		(4.3)		(8.4)		(17.6)
Restructuring charges, net	(11.0)		(3.2)		(17.5)		(15.8)
Non-restructuring impairment charges	—		—		(64.5)		(63.5)
Separation costs (2)	(0.1)		(33.0)		(1.0)		(75.0)
R&D upfront payment (3)	—		—		—		(5.0)
Opioid-related litigation settlement (loss) gain (Note 12)	(125.0)		25.8		(125.0)		34.1
Medicaid lawsuit (Note 12)	—		(0.5)		—		(640.2)
Operating (loss) income	$	(122.6)	$	41.5	$	(129.2)	$	(690.3)

(1)Includes administration expenses and certain compensation, legal, environmental and other costs not charged to the Company's reportable segments.

(2)Represents costs included in SG&A expenses, primarily related to professional fees and costs incurred in preparation for the Chapter 11 proceedings. As of the Petition Date, professional fees directly related to the Chapter 11 proceedings that were previously reflected as separation costs are being classified on a go-forward basis as reorganization items, net.

(3)Represents R&D expense incurred related to an upfront payment made to acquire product rights in Japan for terlipressin.

Schedule of Net Sales from External Customers by Products

Net sales by product family within the Company's reportable segments were as follows:

	Three Months Ended				Nine Months Ended
	September 24, 2021		September 25, 2020		September 24, 2021		September 25, 2020
Acthar Gel	$	143.4	$	195.3	$	423.9	$	576.6
INOmax	98.4		141.9		338.3		438.5
Ofirmev	4.7		88.7		24.0		216.0
Therakos	62.5		62.6		197.8		174.1
Amitiza (1)	49.6		47.7		155.8		138.2
Other	1.1		3.4		9.8		9.6
Specialty Brands	359.7		539.6		1,149.6		1,553.0
Hydrocodone (API) and hydrocodone-containing tablets	16.9		20.0		60.7		71.9
Oxycodone (API) and oxycodone-containing tablets	15.2		16.1		49.5		48.0
Acetaminophen (API)	49.6		54.9		146.8		154.5
Other controlled substances	60.8		62.4		187.9		223.8
Other	5.0		6.0		17.1		14.5
Specialty Generics	147.5		159.4		462.0		512.7
Segment net sales	507.2		699.0		1,611.6		2,065.7
Medicaid lawsuit (Note 12)	—		(0.7)		—		(535.1)
Net sales	$	507.2	$	698.3	$	1,611.6	$	1,530.6

(1)Amitiza consists of both product net sales and royalties. Refer to Note 2 for further details on Amitiza's revenues.